Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Belsomra is an orexin receptor antagonist. Orexin is a neurotransmitter, a chemical in the brain that attaches to the orexin receptor 1 (OX1R) or orexin receptor 2 (OX2R). These receptors regulate ...

Our work has explored the role of the orexin projection to the basal forebrain in attentional processing (Fadel & Burk, 2010). We reported that blockade of orexin-1 receptors with SB-334867, either ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...